Relapses
RELAPSE
The continuous ofatumumab group maintained a low ARR for up to 4 years: adjusted ARRs in the core and extension periods were 0.11 (95% confidence interval (CI): 0.08–0.13) and 0.05 (95% CI: 0.04–0.07), respectively (49.4%; Relapse data: (a) within-group comparison of ARR during the core and open-label extension periods; (b) between-group comparison of total confirmed relapses up to 4 years in the newly switched ofatumumab group and continuous ofatumumab group (efficacy analysis set).Data from the efficacy analysis set. Adjusted ARR presented as ARR (95% CI). ARR: annualized relapse rate; CI: confidence interval; EDSS, Expanded Disability Status Scale; Gd+, gadolinium-enhancing; RR: rate ratio.